Display options
Cite
Diniz MA, Kim S, Tighiouart M. A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate. J Probab Stat. 2018;2018doi: 10.1155/2018/8654173.
Diniz, M. A., Kim, S., & Tighiouart, M. (2018). A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate. Journal of probability and statistics, 2018. https://doi.org/10.1155/2018/8654173
Diniz, Márcio Augusto, et al. "A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate." Journal of probability and statistics vol. 2018 (2018). doi: https://doi.org/10.1155/2018/8654173
Diniz MA, Kim S, Tighiouart M. A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate. J Probab Stat. 2018;2018. doi: 10.1155/2018/8654173. Epub 2018 Nov 01. PMID: 30906326; PMCID: PMC6428433.
Copy Download .nbib Format: NLM
Share it on

J Probab Stat. 2018;2018. doi: 10.1155/2018/8654173. Epub 2018 Nov 01.

A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate.

Journal of probability and statistics

Márcio Augusto Diniz, Sungjin Kim, Mourad Tighiouart

Affiliations

  1. Biostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center 8700 Beverly Blvd, Los Angeles, CA 90048.

PMID: 30906326 PMCID: PMC6428433 DOI: 10.1155/2018/8654173

Abstract

A Bayesian adaptive design for dose finding of a combination of two drugs in cancer phase I clinical trials that takes into account patients heterogeneity thought to be related to treatment susceptibility is described. The estimation of the maximum tolerated dose (MTD) curves is a function of a baseline covariate using two cytotoxic agents. A logistic model is used to describe the relationship between the doses, baseline covariate, and the probability of dose limiting toxicity (DLT). Trial design proceeds by treating cohorts of two patients simultaneously using escalation with overdose control (EWOC), where at each stage of the trial, the next dose combination corresponds to the

Keywords: Baseline covariate; Cancer Phase I trials; Continuous dose; Discrete dose; Dose limiting toxicity; Drug combination; Escalation with overdose control; Maximum tolerated dose

References

  1. J Biopharm Stat. 1999 Mar;9(1):17-44 - PubMed
  2. Biometrics. 2003 Jun;59(2):430-40 - PubMed
  3. Biometrics. 2003 Sep;59(3):487-96 - PubMed
  4. Biometrics. 2005 Mar;61(1):217-22 - PubMed
  5. Stat Med. 2006 Jun 30;25(12):2018-26 - PubMed
  6. Clin Trials. 2004;1(6):499-508 - PubMed
  7. J Clin Oncol. 2008 Feb 1;26(4):563-9 - PubMed
  8. Biometrics. 2009 Sep;65(3):866-75 - PubMed
  9. Biometrics. 2010 Sep;66(3):805-12 - PubMed
  10. Biometrics. 2011 Dec;67(4):1555-63 - PubMed
  11. Cancer Chemother Pharmacol. 2011 Dec;68(6):1439-47 - PubMed
  12. Clin Trials. 2011 Aug;8(4):380-9 - PubMed
  13. Cancer Sci. 2011 Oct;102(10):1868-73 - PubMed
  14. Clin Cancer Res. 2012 May 15;18(10):2954-63 - PubMed
  15. Pharm Stat. 2012 May-Jun;11(3):258-66 - PubMed
  16. Cancer Chemother Pharmacol. 2013 Jun;71(6):1609-17 - PubMed
  17. Stat Med. 2013 Nov 10;32(25):4400-12 - PubMed
  18. Stat Med. 2014 Sep 28;33(22):3815-29 - PubMed
  19. Pharm Stat. 2014 Jul-Aug;13(4):247-57 - PubMed
  20. Stat Med. 2015 Apr 15;34(8):1261-76 - PubMed
  21. Stat Med. 2017 Jan 30;36(2):280-290 - PubMed
  22. Nat Rev Clin Oncol. 2017 Jan;14(1):57-66 - PubMed
  23. Stat Med. 2017 Jul 10;36(15):2323-2332 - PubMed
  24. Am J Biostat. 2016;6(1):1-11 - PubMed
  25. J Biom Biostat. 2017;8(6):null - PubMed
  26. Stat Med. 1998 May 30;17(10):1103-20 - PubMed

Publication Types

Grant support